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1. Introduction  
The disease that has perpetuated the names of two prestigious European physicians, Eugen 
von Hippel and Arvid Lindau, is a familial syndrome characterised by the occurrence of 
highly vascular tumours in different organs¹. Von Hippel-Lindau (VHL) disease is a rare, 
autosomal dominant genetic disease (Online Mendelian Inheritance in Man 193300) that is 
estimated to occur in 1/36,000 live births and with clinical manifestations usually becoming 
apparent between 18 and 30 years. VHL germline mutation predisposes patients to renal 
cysts and carcinoma, central nervous system and retina hemangioblastoma, pancreatic cysts 
and neuroendocrine tumors, pheochromocytoma, endolymphatic sac tumors and 
epididymal or adnexal cystadenoma². Clinical diagnosis requires one major manifestation of 
von HippelLindau disease in patients with a familial history, and at least two major 
manifestations including one haemangioblastoma in isolated cases. Patients are at high risk 
for early multiple and recurrent clear cell Renal Cell Carcinoma (RCC) ³. Total nephrectomy 
was systematically done in the past to prevent the risk of metastatic progression, which led 
to end stage renal disease requiring dialysis. Preserving normal renal parenchyma emerged 
as a major therapeutic goal in VHL cases. Since several groups reported that most RCC in 
VHL cases has low pathological grade, grows slowly and never becomes metastatic at less 
than 3 cm, in the early 1990s Nephron Sparing Surgery (NSS) was developed. The standard 
therapeutic procedure for RCC in VHL cases was to monitor small lesions by imaging and 
perform partial nephrectomy for any RCC that became 2.5 to 3 cm. During the last decade 
percutaneous ablative therapies, such as RFA and cryotherapy that were developed to treat 
localized RCC in select patients emerged as a novel nephron sparing therapy applicable to 
patients with VHL.  
The worldwide von Hippel-Lindau Family Alliance greatly contributes to such 
dissemination by organising International Symposia once every 2 years which are an 
excellent opportunity for doctors, scientists, and affected individuals to meet and exchange 
information on fundamental and clinical issues (http:// www.vhl.org)². 
2. Historical aspects  
Although the contributions of von Hippel and Lindau were decisive, many others played an 
important part in the description of clinical manifestations, but not all can be cited (a 
complete history of von Hippel-Lindau disease is detailed in the articles from Melmon and 
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Rosen, Lamiell and colleagues, and Resche and colleagues )4-6. In 1872, Jackson first 
described a cerebellar haemangioblastoma, and retinal haemangioblastoma was described 
by Panas and Rémy in 18791. 
The first recorded case of a probable patient with von Hippel-Lindau disease was a 35-year-
old woman who died in 1864 with eye and brain tumours7. In 1895 von Hippel described the 
fundoscopic findings in the eye of a 23-year-old man, Otto Mayer, who had presented 2 
years earlier with visual loss. Both the superior temporal artery and vein were dilated and 
supplied a prominent rounded mass located at the periphery of retina8. In 1904, von Hippel 
presented further details of the same patient, who had developed three similar lesions, as 
well as another similar case, of a 28-year-old man9. Von Hippel studied the histological 
characteristics of the right eye of Otto Mayer and concluded in 1911 that the retinal lesion 
was a congenital cystic capillary angiomatosis, which he named angiomatosis retinae10. 
However, it was Arvid Lindau who linked the retinal, cerebral, and visceral components of 
the disease into a single coherent entity in 1926. In his dissertation, he added 16 of his own 
patients to 24 previously reported patients with cystic cerebellar tumours11. He noted that 
cerebellar tumours were frequently associated with retinal lesions but also with renal cysts, 
hypernephroma (renal cell carcinoma), and pancreatic and epididymal cysts. The term von 
Hippel-Lindau disease was first used by Davison and colleagues12 in 1936 and has been in 
common use since the 1970s. In 1964, Melmon and Rosen summarized these data and coined 
the term ‘‘von Hippel-Lindau disease”4.  
 The most recent developments have followed the identification of the VHL gene, first 
located on 3p25–26 in 1988 by Seizinger and colleagues, and fully described in 1993 by Latif 
and coworkers1, 3. 
3. Genetic disorders and renal cell carcinoma 
RCC represents 2-3% of all cancers, 7000 people are diagnosed with RCC each year in the 
UK, and 3600 annually succumb to the disease. It is estimated that 54,390 men and women 
in the United States will be diagnosed with kidney cancer, while 13,010 will die of their 
disease in next year. This number can also be expressed as 1 in 72 men and women will be 
diagnosed with cancer of the kidney during their lifetime and this incidence continues to 
rise13.  
There is an apparent increase in the incidence of RCC of 2.5% per year. This may in part be 
attributed to improved imaging techniques and an increased detection rate of incidental 
lesions. 
Approximately 4% of RCCs are of hereditary origin and VHL is the commonest cause. 
Furthermore, approximately 75% of RCCs are of clear cell histology (cRCC), and VHL is the 
hereditary cause of cRCC14. There are at least six other histological subtypes, each associated 
with a hereditary syndrome15 (table 1). Hereditary cancer syndromes can be difficult to 
identify and early recognition is important, as it facilitates correct management of the 
patient, as well as screening of relatives. Principally, mutations can be ‘‘loss-of-function 
mutations’’ in tumor suppressor genes and ‘‘gain-of-function-mutations’’ in 
protooncogenes, which are then called oncogenes. Research regarding hereditary clear cell 
RCC has led to the identification of a relevant gene locus on the short arm of chromosome 3. 
This loss-off-function mutation led to the assumption of the existence of a tumor suppressor 
gene, and subsequently, further research led to the identification of the VHL gene.  
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Syndrome Gene  
locations 
Relative 
frequency 
Histology Other renal 
abnormalities 
Systemic associations 
VHL 3p26 28- 45% Clear cell Cysts CNS 
haemangioblastoma 
Retinal angiomas 
Pancreatic cysts and 
neoplasm 
Phaeochromocytoma 
Tuberous  
sclerosis 
9q34, 
16p13 
1-2% Clear cell Cysts, 
papillary, 
oncocytoma 
CNS tubers 
Cutaneous 
angiofibromas 
Hereditary  
papillary RCC 
7q34 19% Papillary  
type 1 
None  None known 
Birt-Hogg- Dube 17p11 8-15% Chromophobe Clear cell, 
papillary, 
oncocytoma 
Lung cysts 
Pneumothorax 
Lynch type 2 2p16, 
3p31 
2-9% Transitional 
cell 
carcinoma 
None Carcinoma of colon, 
ovary, 
endometrium, 
stomach 
Medullary carcinoma 
of the kidney 
11p Unknown Medullary 
carcinoma 
None Sickle cell trait 
Hyperparathyroidism 
Jaw tumour 
1q25 Unknown Papillary Cysts Parathyroid tumours 
Fibro-osseous 
mandibular/ 
maxillary tumours 
Familial papillary 
thyroid 
cancer 
1q21 Unknown Papillary Oncocytoma  Papillary thyroid 
cancer 
Nodular thyroid 
disease 
Table 1. The hereditary renal cancer syndromes 
In the early 1980s, the search to identify a loss of heterozygosity in one of the alleles of a 
cancer gene was initiated, with the hope that loss of heterozygosity would indicate the 
presence of a cancer gene at that location. A tumor suppressor gene requires loss of function 
or inactivation of one or both of the genes, often by mutation of 1 allele combined with 
deletion, or loss, of the second allele, whereas, an oncogene is activated by 1 change in the 
gene. In the initial studies, loss of segments at chromosome 3 in tumor tissue suggested that 
a cancer gene for kidney cancer was present at this location16. Dr Knudson’s “two hit” 
theory postulates that most tumor suppressor genes encode proteins responsible for the 
negative regulation of cellular growth. A mutation that causes a loss of the function in one 
these proteins will lead to tumorigenesis or uninhibited cell growth. As the gene of interest 
for clear cell kidney cancer was too large to localize with the technology that was available 
at the time, an approach focusing on a hereditary form of kidney cancer, von Hippel-
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Lindau, was used as the model of investigation. The hope was that the gene involved in 
hereditary kidney cancer may involve the same gene as in the sporadic form of kidney 
cancer17. Lubensky and colleague performed a study that supported the two-hit theory of 
inheritance in VHL disease. The makeup of 26 renal cysts was studied with microdissection 
techniques. They found that each cyst was lined with a single layer of clear epithelial cells. 
Twenty-five of the 26 cysts had a mutation of the wild-type allele; in only one case was the 
usual heterozygosity of the disease maintained. This finding supports two-hit theory: once 
the heterozygosity for VHL is lost in a specific organ, in this case the kidney, the cyst can 
progress into a tumor18. 
4. Genetics in von Hippel-Lindau  
Consistent loss of the short arm of chromosome 3 in VHL associated kidney tumors was 
identified19. Genetic linkage analysis was utilized to help identify the VHL gene, which was 
identified on the short arm of chromosome 3p20. The loss of the single normal allele of the 
VHL gene in the kidney cancer cell samples was critical and suggested that there was an 
inherited gene at this location, which was associated with the development of VHL-
associated clear cell kidney cancer. Germline mutations on the VHL gene are identified in 
nearly 100% of VHL families21. The disease is caused by germline mutations in the VHL 
tumour-suppressor gene; the same gene is inactivated in most cases of sporadic renal-cell 
carcinoma and Central Nervous System (CNS) haemangioblastomas. The VHL gene seems 
to be pivotal in the processes of angiogenesis, an oxygensensing pathway involving the 
hypoxia-inducible factor (HIF), a heterodimeric transcription factor. The VHL gene product 
targets the subunit of HIF for polyubiquitylation and proteasomal degradation. This is the 
rationale for development of specific inhibitors of hypoxia-inducible factors and their 
downstream targets, which lead to potential new treatments. The development of a second 
mutation causing deletion of the normal VHL allele leads to tumor formation in affected 
individuals. More than 300 different types of mutations have been described that involve the 
three exons of the VHL gene. 
The different clinical manifestations of VHL can be associated with the location and type of the 
VHL gene mutation22, 23. Penetrance of the traits is far from complete, and for some such as 
pheochromocytomas, they tend to be clustered in certain families but do not occur in others24. 
Maranchie et al.25 identified a significantly higher incidence of renal cell carcinoma in patients 
with partial germline VHL mutations vs. those with complete VHL gene mutations. It is now 
known that with mutation analysis (e.g., insertion, deletion, missense, or nonsense) and the 
location (e.g., codon position) of the mutation, correlations can be made to the phenotype, i.e., 
the extent of involvement of the various organ systems affected by VHL. 
Germline mutations in VHL have been identified in almost all patients with von Hippel-
Lindau disease and correlations between the genotype and the phenotype are emerging, 
confirming clinical distinction based on the presence or absence of phaeochromocytoma. 
Such mutations have been identified in several patients without classic clinical criteria and a 
diagnosis of von Hippel-Lindau disease must now be considered in patients with an 
apparently sporadic tumour, especially in the case of phaeochromocytomas. Specific 
germline mutations in VHL have been associated with a rare recessive haematological 
condition (Chuvash polycythaemia) and might also be implicated in some sporadic 
apparently congenital polycythaemias26.  
www.intechopen.com
 Renal Tumors in Patients with von Hippel-Lindau Disease: “State of Art Review” 97 
The function of the VHL gene has been evaluated extensively. It is a small gene that encodes 
854 nucleotides on 3 exons and is responsible for encoding the VHL protein20. The VHL 
protein forms a complex with proteins including elongin C, elongin B, and Cul-227-29 and 
targets the @ subunits of the hypoxia inducible factors, such as HIF-@ and HIF-2@, which 
are instrumental to ubiquitin mediated degradation30. There are multiple downstream 
genes, such as Glut 1 (glucose transport), vascular endothelial growth factor (VEGF, blood 
vessel growth), epidermal growth factor (EGF), transforming growth factor (TGF-@), for 
which HIF regulates. The expression of these genes increases in clear cell carcinoma when 
the VHL gene is inactivated (figure 1). Many of the receptors for HIF regulated genes are the 
targets for the new targeted therapeutic approaches for clear cell carcinoma31. Studies have 
shown that if the VHL complex is unable to bind to the HIF proteins, tumorigenesis results. 
Mutations in the oxygen-dependent domain or the VHL binding site of HIF-2-@, but not of 
HIF-1-@, result in tumorigenesis in xenograft models. Kondo and colleagues33 showed that 
inhibition of only HIF-2-@ suppresses pVHL deficient tumor growth. This finding 
established that HIF-2-@ is a critical component to tumorigenesis in clear cell RCC. As 
previously discussed, HIF proteins are key regulators of oxygen homeostasis, and tight 
regulation of HIF allows cell survival and growth at the time of hypoxic stress. HIF acts via 
transcriptional regulation of VEGF, PDGF, EGFR, GLUT1, erythropoietin, and TGF-@. Loss 
of VHL is thought to result in a pseudohypoxic state, so that cellular response pathways 
mediated by HIF are activated despite normal oxygen conditions. 
Understanding the VHL pathway and these pseudohypoxic pathways has provided the 
opportunity to develop therapies that target the downstream HIF pathway genes VEGF and 
PDGF with agents such as sunitinib that have a high affinity for the VEGF and PDGF 
receptors. 
Other strategies, such as targeting HIF transcription and HIF stability, also are being 
evaluated in clinical trials.  
5. Clinical diagnosis  
VHL disease is among the group of disorders known as ‘‘phakomatoses’’ in which lesions 
arise from a single germ layer. The lesions of VHL disease are primarily mesodermal in 
origin. The clinical manifestations of VHL disease span a spectrum of phenotypic variability. 
It has virtually complete penetrance but variable expressivity. The syndrome is 
characterized by multiple tumor types, including kidney tumors, pheochromocytomas, 
epididymal cystadenomas, retinal angiomas, hemangiomas of the CNS, and pancreatic islet 
cell tumors. 
Diagnosis of von Hippel-Lindau disease is often based on clinical criteria. Patients with a 
family history, and a CNS haemangioblastoma (including retinal haemangioblastomas), 
phaeochromocytoma, or clear cell renal carcinoma are diagnosed with the disease. Those 
with no relevant family history must have two or more CNS haemangioblastomas, or one 
CNS haemangioblastoma and a visceral tumour (with the exception of epididymal and renal 
cysts, which are frequent in the general population) to meet the diagnostic criteria4, 34. 
Specific correlations of genotype and phenotype have emerged in affected families. Several 
familial phenotypes of von Hippel-Lindau disease are now recognised, providing useful 
information to screen and counsel affected individuals. Type 1 families have a greatly 
reduced risk of phaeochromocytomas, but can develop all the other tumour types generally 
associated with the disease. Type 2 families have phaeochromocytomas, but have either a 
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low-risk (type 2A) or high-risk (type 2B) for renal cell carcinomas. Type 2C families have 
phaeochromocytomas only, with no other neoplastic findings of VHL (table 2)35.  
 
 
Fig. 1. 70 The VHL gene complex targets hypoxia-inducible factors (HIF) for ubiquitin-
mediated degradation. When there is a mutation in the VHL gene in clear cell kidney cancer, 
in either the elongin binding or the HIF binding domain (A), HIF is not degraded and this 
protein over-accumulates. Increased HIF levels lead to increased transcription of a number 
of downstream pathway genes that are thought to be important in kidney cancer, such as 
vascular endothelial growth factor (VEGF), the glucose transporter, GLUT1, and 
transforming growth factor _ (TGF-@) (B). Targeted approaches to therapy currently include 
tyrosine kinase inhibitors that target the downstream gene receptors (C). Other approaches 
being developed to target the VHL-HIF pathway in clear cell kidney cancer include the 
development of small molecules or other agents which block HIF transcription. Reprinted 
from Linehan et al32. 
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 Clinical characteristics  
Type 1 Retinal haemangioblastomas 
CNS haemangioblastomas 
Renal cell carcinoma 
Pancreatic neoplasms and cysts 
Type 2A Phaeochromocytomas 
Retinal haemangioblastomas 
CNS haemangioblastomas 
Type 2B Phaeochromocytomas 
Retinal haemangioblastomas 
CNS haemangioblastomas 
Renal cell carcinomas 
Pancreatic neoplasms and cysts 
 
Type 2C Phaeochromocytoma only 
*Endolymphatic sac tumours and cystadenomas of the epididymis and broad ligament have not been 
assigned to specific von Hippel-Lindau types. 
Table 2. Genotype-phenotype classifications in families with von Hippel-Lindau disease* 
The age of onset of VHL disease is variable and depends both on the expression of the 
disease within the individual and within the family and on the screening protocol used to 
detect asymptomatic lesions. More intensive screening regimens can increase greatly the 
number of affected individuals discovered in a family. Retinal lesions generally are the first 
lesions to be diagnosed.  
Of the non-urologic stigmata, the most common in patients who survive to age 60 years are 
retinal angiomas, which affect 70% of patients, and CNS hemangiomas, which affect 84% of 
patients. The urologic manifestations include renal clear cell carcinoma (RCC), 
pheochromocytoma, and epididymal cystadenomas, which affect approximately 40%, 18%, 
and 10% of patients, respectively. Approximately a third of the patients who have VHL 
disease (13%–42%) die of metastatic disease.  
The median age of death from VHL disease is 49 years, and the most common causes of 
death are neurologic complications of cerebellar haemangioblastoma and metastatic renal 
carcinoma. Approximately 53% of patients who have VHL disease die of complications of 
cerebellar hemangioblastoma, and 32% die of metastatic RCC36. 
6. Screening and surveillance for von Hippel-Lindau disease  
Genetic testing for VHL is widely available and involves a simple blood test with an 
accuracy approaching 100% if the mutation is known37. However, the test is only available 
in select laboratories. Antenatal diagnosis is also feasible. In the past 15 years there have 
been major changes in the management of VHL. Better surveillance and genetic testing have 
improved detection rates of presymptomatic RCCs and these can now be treated with 
nephron-sparing procedures (NSS) before metastatic disease develops, preserving renal 
function as far as possible, but as yet there are no standardized screening protocols for VHL 
and guidelines vary between institutions.  
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The screening process for patients who have hereditary renal tumor syndromes developed 
at the Clinical Center of the National Institutes of Health (NIH) (table 3) includes 
karyotyping for the germline mutations of the VHL gene; abdominal CT with and without 
intravenous contrast material injection; renal ultrasound; ophthalmologic examination; 
brain, spinal, and internal auditory canal MRI; scrotal ultrasound for male patients; chest 
radiograph; and 24-hour urine and plasma catecholamines38. 
 
 PROTOCOL 
Urinary catecholamines From age 2 years: every 
1-2 years 
Opthalmoscopy From infancy: yearly 
Enhanced magnetic 
resonance imaging of 
brain and spine 
From age 11: every 2 years 
From age 60: every 3-5 years 
Abdominal computed 
tomography or 
ultrasound 
From age 11: ultrasound yearly 
From age 20: computed 
tomography every 1-2 years 
This is the protocol used at the National Institute of Health, USA.  
Table 3. Screening of patients with Von Hippel- Lindau disease 
The primary goals of preoperative evaluation for RCC are to define renal anatomy and to 
identify tumors in the brain, eye, pancreas, and adrenal glands that may present an 
intraoperative risk if undiagnosed. Such lesions include pheochromocytomas, which would 
require catecholamine blockade and probably resection at the time of renal surgery, and 
hemangioblastomas, which carry the risk of hemorrhage at the time of induction of anesthesia. 
Pancreatic neuroendocrine tumors also might be excised at a single surgical setting. 
MRI can demonstrate CNS abnormalities most clearly while adequately imaging the 
abdominal viscera. CT, however, is the most accurate method of screening and follow-up for 
RCC. In addition to CT or MRI, an angiogram may be obtained preoperatively to define 
patient renal arterial anatomy before the first surgery. One study showed that angiogram 
identified only 16% of the multiple small renal tumors that were present 39, making it of 
limited utility beyond providing a vascular map for the first resection (but few hospitals 
perform this technique).  
After surgical treatment for renal tumors, patients should be screened regularly to monitor 
for recurrence, metastasis, and loss of renal function. Periodic history and physical 
examination, routine laboratory screening tests, abdominal CT, renal ultrasound, chest CT 
or radiograph, and renal scans can be performed in addition to monitoring for new 
manifestations of VHL disease with periodic brain and spine MRIs, urinary catecholamines, 
and ophthalmologic evaluation40.  
Family members who carry a germline mutation but have not developed a tumour, and 
those with a mild phenotype can safely be imaged every 2-3 years. However, patients with 
mutations predisposing them to RCC should be assessed more frequently at 6-12 monthly 
intervals, depending on tumour growth rates41. Genetic testing can help predict the risk of 
developing RCC (as discussed above). Recent studies42 have linked specific mutations to 
more aggressive forms of RCC and poorer survival rates. Such genetic stratification may 
allow more specific or patient focused surveillance in the future.  
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7. Renal cell carcinomas and renal cysts in von Hippel Lindau general 
features 
Renal cell carcinomas are the major malignant neoplasm in von Hippel-Lindau disease and 
the primary cause of inherited renal cancer. These tumours are seen in 24–45% of patients, 
and adding renal cysts increases the finding of renal lesions to 60%. Renal disease is 
multicentric and bilateral in at least 75% of patients who have VHL disease. The mean age at 
presentation is 39 +/- 10 years, which is 10 to 20 years earlier than that reported for sporadic 
renal disease. 
In addition to the young age of presentation, RCC associated with VHL disease also recurs 
frequently years. Although small renal tumours in this disease tend to be low grade and 
minimally invasive, their rate of growth varies widely43. Renal lesions are often multiple and 
bilateral. Walther and colleagues44 estimated that 600 microscopic tumours and 1100 
microscopic clear-cell-lined cysts might be present in the kidneys of some 37-year-old 
patients. Results of an investigation of 228 renal lesions in 28 patients, followed for at least 1 
year, showed that transition from a cyst to a solid lesion was rare. Solid tumors in VHL 
disease have been observed to grow at rates of 0.2 to 2.2 cm/year (mean, 1.6 cm/year), 
which is somewhat faster than rates observed in sporadic RCC. The change that occurs in 
renal lesions over time in patients who have VHL disease is generally slow and constant, 
but it has been followed in only a small number of cases 45. 
 However, complex cystic and solid lesions can contain neoplastic tissue that frequently 
enlarges. Renal cell carcinomas often remain asymptomatic for long intervals. Thus, serial 
imaging of the kidneys is useful for early diagnosis. Occasionally, the more advanced cases 
with these neoplasms can present with haematuria, flank pain, or a flank mass. Renal cysts 
in von Hippel-Lindau disease are typically asymptomatic and seldom need treatment. Renal 
cysts are present in 59% to 63% of patients who have VHL disease, and some studies believe 
the number may be as high as 85% Cysts generally preceded the detection of solid tumors 
by about 3 to 7 years. Studies have shown that at least 21% of cystic renal lesions contain foci 
of RCC and RCC is reported to develop in 24% to 45% of patients who have VHL disease. 
Therefore, complex cysts need monitoring, as they often harbour solid components of renal 
cell carcinoma. Because of the frequent absence of early clinical symptoms and the 
importance of early detection, diagnosis during presymptomatic screening has the potential 
to enhance overall outcome.  
Contrast-enhanced abdominal CT is the standard for detection of renal involvement in the 
disease. CT allows detection and quantification by size and number of renal cell carcinomas 
and cysts, allowing serial monitoring of individual lesions. Imaging is usually 
recommended in 3–5 mm sections, and before and after intravenous injection of contrast 
media. Precontrast and postcontrast MRI is an alternative method of detection for patients 
who have reduced renal function. These carcinomas are yellow or orange and are 
encapsulated. They can be solid or a mixture of solid and cystic in appearance. 
Histologically, they are always of the clear-cell subtype, and small carcinomas tend to be 
low grade. In addition, microscopic examination of small VHL renal lesions consistently 
demonstrated a pseudo-capsule surrounding these low-grade renal lesions. This pseudo-
capsule has since proven to facilitate tumor resection by forming a natural tissue plane for 
dissection46 . The recurrence rate of renal tumors is high in patients who have VHL disease. 
Examination of normal renal tissue of patients who have RCC and VHL disease has shown 
multiple microscopic renal tumors 43. Treatment recommendations depend on tumour size.  
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8. Radiology of renal masses in VHL 
RCC in VHL usually manifests as a complex cystic mass, which is also the most difficult 
type of renal lesion to accurately assess, especially when detected incidentally. The Bosniak 
classification was first described in 1986 and determines the management approach to the 
sporadic cystic renal mass47. The system was devised for CT but can also be applied to MRI.  
As some patients with VHL require long-term follow-up of renal manifestations with cross-
sectional imaging, there are clear advantages of MRI, such as the absence of radiation. CNS 
manifestations are almost exclusively imaged with MRI in most institutions. MRI has also 
proved more accurate at assessing cystic pancreatic lesions and distinguishing 
phaeochromocytoma from adenoma on chemical shift imaging. It is also more sensitive than 
CT in detecting neuroendocrine tumours of the pancreas. For these reasons, several authors 
advocate annual surveillance of abdominal manifestations with MRI. These advantages 
must be weighed against potential risks of nephrogenic systemic fibrosis (NSF) with 
gadolinium compounds when used in renal impairment, as well as logistical factors, such as 
cost and limited access of MRI at some institutions. However, patients undergoing a lifetime 
of screening may accumulate relatively large doses of radiation to the kidneys as a 
consequence of annual screening with CT. Thus, there is no clear-cut answer which is the 
best imaging modality48. 
Before CT was widely available 13-42% of patients with VHL died of metastatic RCC43. The 
discovery of the VHL gene in 1993 unlocked a better understanding of the pathways 
involved in tumourigenesis. Surgery is still the only curative treatment of RCC. Bilateral 
nephrectomy with renal-replacement therapy would eradicate all tissue at risk for 
developing RCC and is a theoretical, but radical, option in a patient with VHL. However, 
patients with VHL do worse on renal-replacement therapy. A large study49 showed a 5-year 
survival rate of 65% in VHL patients on dialysis compared with 71-86% for the non-VHL 
group. But renal impairment in the absence of renal surgery is rare among VHL patients. As 
patients with VHL do worse with renal- replacement therapy, the aim of successful 
management is to preserve renal function balanced against the risk of developing renal 
metastatic disease. The secondary aim is to minimize the number of procedures performed 
to accomplish this. To accomplish these aims accurate imaging-guided diagnosis and 
nephron-sparing procedures are important. 
9. Nephron-sparing surgery and other treatments in von Hippel-Lindau 
disease 
RCC in von Hippel-Lindau disease differs from its sporadic counterpart in that the 
diagnosis is made at a young age, and there are usually multiple bilateral renal tumors. 
Although these are generally low-stage tumors, they are capable of progression with 
metastasis and represent a frequent cause of death in patients with von Hippel-
Lindau disease. RCC in these patients is characterized histopathologically by both solid 
tumors and renal cysts that contain either frank carcinoma or a lining of hyperplastic clear 
cells representing incipient carcinoma. 
Therefore, adequate surgical treatment of localized RCC in vonHippel-Lindau disease 
requires excision of all solid and cystic renal lesions. Choyke et al.50 have shown that 
intraoperative ultrasonography may be a valuable adjunct for this population of patients. In 
their series, this study identified additional tumors in 25% of patients with hereditary renal 
cancer undergoing renal exploration. 
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The surgical options in patients with bilateral RCC and von Hippel-Lindau disease are 
bilateral nephrectomy and renal replacement therapy or partial nephrectomy to avoid end-
stage renal failure. The general philosophy has been to pursue nephron-sparing surgery if 
possible, given the multifocal nature of the disease, even for centrally located tumors. The 
treatment options for patients who have renal involvement in VHL disease have evolved 
during the last 3 decades. Staged bilateral nephrectomy and hemodialysis have progressed to 
partial nephrectomy and NSS. The best management approach for VHL disease balances the 
goals of minimizing the risk of RCC metastasis and preserving renal function and attempts to 
minimize the total number of surgeries a patient will require over a lifetime51 . There are no 
specific guidelines regarding the type or timing of surgery in patients who have VHL disease. 
The treatment strategy of total nephrectomy and Renal Replacement Theraphy (RRT) 
removes all the tissue at risk for RCC and, with it, the risk of metastases. Goldfarb and 
colleagues52 noted a 5-year survival rate of 65% in patients who had VHL disease and who 
were treated with bilateral nephrectomy and RRT. Some transplant centers consider the 
presence or potential for VHL-related tumors, including renal and extrarenal tumors, a 
contraindication for renal transplantation. 
The indications for NSS are localized malignancy in a solitary kidney, bilateral synchronous 
renal lesions, and renal tumors in patients whose contralateral kidney is threatened by local, 
systemic, or genetic risk factors53.  
Although early results of partial nephrectomy were promising, subsequent studies 
suggested a high incidence of postoperative tumour recurrence in the remaining portion of 
the kidney. It is likely that most of these local recurrences were a manifestation of residual 
microscopic RCC that was not removed at the time of the original partial nephrectomy. 
Walther and colleagues54 have reported extensively on their approach of enucleation of 
small renal tumors associated with VHL disease (figure 2). Preservation of the perirenal fat 
and fascia are believed to be important in improving the patient’s ability to undergo 
subsequent renal surgeries. The renal capsule is incised, circumscribing the lesions to be 
resected. All cystic lesions are excised, if possible, because of the potential for development 
of RCC46. Smaller cystic lesions are unroofed, and the base is fulgurated (however it has not 
been shown that this is completely safe). 
A study from the NIH55 showed that renal tumors less than 3 cm in size are not considered 
an indication for radical surgery. Patients who have VHL disease generally are followed 
expectantly until solid renal lesions are larger than 3 cm in diameter. In the previously 
mentioned NIH study, the 3-cm threshold for surgery was evaluated in 52 patients who had 
VHL disease. None of these patients had metastatic disease, and none required RRT. Forty-
six of these patients underwent NSS rather than radical nephrectomy. Forty-four patients 
who had VHL disease developed renal tumors larger than 3 cm. From this study, the 
authors concluded that using a 3-cm tumor diameter as a threshold for NSS may help 
prevent metastatic disease. These authors also noted the importance of intraoperative 
Doppler ultrasound for locating tumors and verifying that all tumors have been removed56. 
A follow-up of this study38 revealed that metastasis did not develop in any patient who had 
a solid renal tumor smaller than 3 cm. Of 50 patients who had RCC, metastasis developed in 
1 patient who had a primary renal tumor that was 4.5 cm in greatest diameter.  
One multicenter study57 delineated the long-term outcomes after surgical treatment of 
localized RCC in 65 patients with von Hippel-Lindau disease managed at eight medical 
centers in the United States. RCC was present bilaterally and unilaterally in 54 and 11 
patients, respectively. Radical nephrectomy and partial nephrectomy were performed in 16 
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and 49 patients, respectively. The mean postoperative follow-up interval was 68 months. 
The 5-year and 10-year cancer-specific survival rates for all patients were 95% and 77%, 
respectively. The corresponding rates for patients treated with partial nephrectomy were 
100% and 81%, respectively. In the latter group, 25 patients (51%) developed postoperative 
local recurrence; however, only two of these patients had concomitant metastatic disease. 
Survival free of local recurrence was 71% at 5 years but only 15% at 10 years. Only 2 of 25 
patients who had local recurrence after NSS had metastatic disease at the time recurrence 
was detected.  
 
 
Fig. 2. Intraoperative photograph of multiple tumors and cysts in the kidney in a patient 
who has VHL disease. 
Similarly, Roupret et al.58 reported a 27.4% incidence of local recurrence at mean follow-up 
of 55.9 months after partial nephrectomy for patients with von Hippel-Lindau disease, 
confirming that these patients are at much higher risk for local recurrence than are patients 
with sporadic RCC. Ploussard and colleagues59 published a series to evaluate the risks of 
local recurrence after NSS in patients who have VHL disease. Seventeen of 21 patients 
underwent surgery for RCC when tumors reached 3 cm. Eight patients developed a 
recurrence, and the mean time to local recurrence was 53+/- 38.8 months (range, 10–115 
months). The disease-specific survival rate was 93.8% at 10 years. No metastasis or chronic 
renal insufficiency was observed in patients undergoing NSS only. 
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Taken together, these studies suggest that partial nephrectomy can provide effective initial 
treatment of patients with RCC and von Hippel-Lindau disease but should be withheld 
until tumor size reaches or eclipses 3.0 cm. Studies show that up to 85% of patients who 
have VHL disease experience de novo renal tumor recurrence at 10 years57.  
After nephron-sparing surgery, patients with von Hippel-Lindau disease must be observed 
closely because most will eventually develop locally recurrent RCC with the concomitant 
need for repeated renal surgery. In this setting, repeated partial nephrectomy can be 
challenging because of postoperative fibrosis, and some centers are moving toward thermal 
ablative modalities to reclaim local control and many surgeons are reluctant to perform 
additional NSS because of complications related to postoperative fibrosis60. These salvage 
surgeries were greatly complicated by severe fibrosis, scarring, and the obliteration of 
normal anatomic planes. The authors concluded that aggressive surgical intervention in 
these patients is indicated, because none of the patients developed metastatic disease as long 
as 7 years after surgery, and there was 100% survival in this cohort61. NSS has been 
performed using the laparoscopic approach in select centers, but the inability to achieve 
reliable hypothermia along with prolonged ischemia times and increased complication rates 
have limited in its widespread application. At present, open NSS should be considered the 
standard of care for treating RCC in the setting of VHL disease. 
When removal of all renal tissue is necessary to achieve control of malignant disease, renal 
transplantation can provide satisfactory replacement therapy for end-stage renal disease 
and appears to be safe despite the tumor diathesis.  
Newer, minimally invasive techniques62, such as radiofrequency ablation and cryoablation, 
have been applied recently as an alternative to excisional NSS in patients who have RCC. 
Ablative techniques may63, 65 be performed by laparoscopic and percutaneous image-guided 
techniques. Jolly et al.64 concluded in a recent published article that renal survival in patients 
with VHL who are treated for RCC has improved with time. Their renal survival curves 
actually reflect the decreasing need to remove all renal tissue to achieve local control of 
malignancy, in parallel with improved NSS and the emergence of renal salvage techniques 
such as Radio Frecuency Ablation (RFA) (figure 3a and 3b). As well as surgery, nephron 
sparing procedures now include RFA and cryoablation. In their experience since 2004 RFA 
has become the exclusive salvage technique. Overall a third of RFA sessions were performed 
in single functioning kidneys, including 8 in a total of 8 patients who had already been 
operated on twice and were not candidates for additional NSS. 
These all have a role in the surgical management of VHL-associated RCC and experience of 
these newer modalities in VHL is increasing, and good preliminary success rates are being 
published. A small study by Shingleton and Sewell66 reported the successful treatment of 
five small RCCs in four patients with VHL using MRI-guided cryoablation, but greater 
evidence is available for imaging- guided RFA treatment of RCCs in the context of VHL, 
demonstrating good success rates for exophytic tumours of up to 5 cm in size67, 68. 
In conclusion69, as patients with VHL with RCC are increasingly treated with nephron 
sparing techniques, especially RFA, it must be remembered that only long-term follow-up 
can hopefully confirm that no unexpected metastasis develops beyond increased renal 
survival. In patients who have a single kidney or multiple bilateral lesions, collateral 
damage to normal renal parenchyma must be considered. For patients who have VHL 
disease, and all patients who have hereditary cancer syndromes, the goal of treatment is 
cancer control, not cancer cure, and preservation of functional parenchyma to avoid the 
morbidity associated with renal or adrenal loss. 
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Fig. 3a. Renal tumor in a patient with solitary right kidney and VHL disease  
 
 
Fig. 3b. Contrast enhanced CT scan after radiofrequency ablation show the absence of 
contrast enhancement in the ablated area. 
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